Evidence map›Paper›PMID 37611129›Full record

ArticleThe New England journal of medicine2023

Anti-Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia.

Soravis Osataphan, Maria Vamvini, Evan D Rosen, Lei Pei, Natanie Erlikh, Gurcharan Singh, Poojaben Dhorajiya, J Anthony Parker, Jonathan M Dreyfuss, Ahmed Rattani and 1 more

Abstract readLetter
In one paragraph

Article in The New England journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors.The Journal of clinical endocrinology and metabolism · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Approach to the Patient: Insulinoma.The Journal of clinical endocrinology and metabolism · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Soravis OsataphanBeth Israel Deaconess Medical Center, Boston, MA.ORCID 0000-0002-6503-4418
Maria VamviniJoslin Diabetes Center, Boston, MA.
Evan D RosenBeth Israel Deaconess Medical Center, Boston, MA.
Lei PeiBeth Israel Deaconess Medical Center, Boston, MA.
Natanie ErlikhBeth Israel Deaconess Medical Center, Boston, MA.
Gurcharan SinghBeth Israel Deaconess Medical Center, Boston, MA.
Poojaben DhorajiyaBeth Israel Deaconess Medical Center, Boston, MA.
J Anthony ParkerBeth Israel Deaconess Medical Center, Boston, MA.
Jonathan M DreyfussJoslin Diabetes Center, Boston, MA.
Ahmed RattaniBeth Israel Deaconess Medical Center, Boston, MA.
Mary-Elizabeth PattiJoslin Diabetes Center, Boston, MA maryelizabeth.patti@joslin.harvard.edu.ORCID 0000-0002-8163-3429

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5M
TRAINING IN DIABETES AND METABOLISMT32DK007260 · NIDDK · JOSLIN DIABETES CENTER · PI LAURIE J GOODYEAR · 1986 to 2026
$13.6M
Mechanisms of Post-Bariatric HypoglycemiaR01DK121995 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PATTI, MARY E, SANDOVAL, DARLEEN A. · 2019 to 2022
$2.8M
NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30DK036836NIDDK NIH HHS R01 DK121995NIDDK NIH HHS R01DK121995NIDDK NIH HHS T32 DK007260
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HypoglycemiaInsulinInsulin AntagonistsInsulinomaPancreatic NeoplasmsAntibodiesHumansAntibodiesInsulinInsulin Antagonists

Identifiers

PMID37611129
PMCPMC10506502

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.